The role of plasmapheresis in acute renal failure

Acute kidney injury (AKI), conditions that occur with the accumulation of blood urea nitrogen, creatinine and other uremic toxins, and the acceleration of glomerular filtration (GFR) rate. It is the site of plasmapheresis to clear some that cause AKI clinic, and plasmapheresis (PZ) is the plasma evacuation of the targeted part to remove it from the blood. Plasmapheresis immunocomplexes exclude acute overprogression by clearing virus cells from plasma. In addition, these cells increase the potency of plasmapheresis, immunosuppressive and/or immunomodulatory cells. It is aimed to compare the clinic of acute harmful organisms due to systemic lupus erythematosus (SLE), vasculitis, hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP), and those who were discharged in the early and late period before and after the plasmapheresis procedure involving their cells in our study center. A total of 35 patients were included in the study.Ten of the patients (28.6%) were diagnosed with ANCA+ vasculitis, 18 (51.4%) were diagnosed with thrombotic microangiopathy (TMA), and 7 patients (20%) were diagnosed with SLE. The mean number of patients receiving plasmapheresis was 9.43 ± 7.44. The mean GFR of the patients before plasmapheresis was 23.14 ± 20.38 ml/min, 62.77 ± 40.9 ml/min in the first month control after plasmapheresis, 73.91 ± 41.79 ml/min in the third month control, 70 in the first year control. It was found to be .1 ± 41.02 ml/min (p=0.001). In ANCA + vasculitis patients, GFR was 14.4 ± 9.54 ml/min before plasmapheresis, and GFR was 31.7 ± 32.21 ml/min in the first month control after plasmapheresis; In the third month control, it was found to be 39 ± 33.07 ml/min and a significant increase was observed in the GFR value compared to the pre-procedure. When the patients with TMA diagnosis were examined, the mean GFR was 26.89 ± 24.87 ml/min before plasmapheresis, and the first month measurement after plasmapheresis was 84. 17 ± 34.9 ml/min, the first year measurement was 88 ± 37.3 ml/min (p=0.001) (p=0.002). In patients diagnosed with SLE, GFR was 73.71 ± 37.97 ml/min and 74.57 ± 41.33 ml/min in the third month and first year controls after plasmapheresis, and a significant improvement was observed compared to the baseline level. In these patients, a significant decrease in GFR was detected with plasmapheresis in the early period, and renal functions were preserved at the end of the first year.